AR083066A1 - PHARMACEUTICAL COMPOSITION - Google Patents

PHARMACEUTICAL COMPOSITION

Info

Publication number
AR083066A1
AR083066A1 ARP110103435A AR083066A1 AR 083066 A1 AR083066 A1 AR 083066A1 AR P110103435 A ARP110103435 A AR P110103435A AR 083066 A1 AR083066 A1 AR 083066A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
composition
kit
formulation
making
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Jose Iturraspe
Jose Lucio Nuez
Jose Castillo
Original Assignee
Eriochem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eriochem Sa filed Critical Eriochem Sa
Priority to ARP110103435 priority Critical patent/AR083066A1/en
Priority to BR112013029758-1A priority patent/BR112013029758A2/en
Priority to US14/117,958 priority patent/US9029582B2/en
Priority to PCT/ES2012/070267 priority patent/WO2012160223A1/en
Priority to CA2836831A priority patent/CA2836831C/en
Priority to ES12789794T priority patent/ES2708302T3/en
Priority to EP12789794.0A priority patent/EP2711010B1/en
Priority to MX2013013558A priority patent/MX2013013558A/en
Publication of AR083066A1 publication Critical patent/AR083066A1/en
Priority to US14/629,958 priority patent/US20150202210A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composición farmacéutica sólida que comprende fulvestrant sólido amorfo. Formulación de dicha composición en combinación con una composición solubilizante. El proceso de elaboración de dicha composición y un kit que la comprende.Solid pharmaceutical composition comprising amorphous solid fulvestrant. Formulation of said composition in combination with a solubilizing composition. The process of making said composition and a kit that includes it.

ARP110103435 2011-05-20 2011-09-20 PHARMACEUTICAL COMPOSITION AR083066A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ARP110103435 AR083066A1 (en) 2011-09-20 2011-09-20 PHARMACEUTICAL COMPOSITION
BR112013029758-1A BR112013029758A2 (en) 2011-05-20 2012-04-23 pharmaceutical composition
US14/117,958 US9029582B2 (en) 2011-05-20 2012-04-23 Pharmaceutical composition
PCT/ES2012/070267 WO2012160223A1 (en) 2011-05-20 2012-04-23 Pharmaceutical composition
CA2836831A CA2836831C (en) 2011-05-20 2012-04-23 Pharmaceutical composition
ES12789794T ES2708302T3 (en) 2011-05-20 2012-04-23 Pharmaceutical composition
EP12789794.0A EP2711010B1 (en) 2011-05-20 2012-04-23 Pharmaceutical composition
MX2013013558A MX2013013558A (en) 2011-05-20 2012-04-23 Pharmaceutical composition.
US14/629,958 US20150202210A1 (en) 2011-05-20 2015-02-24 Pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP110103435 AR083066A1 (en) 2011-09-20 2011-09-20 PHARMACEUTICAL COMPOSITION

Publications (1)

Publication Number Publication Date
AR083066A1 true AR083066A1 (en) 2013-01-30

Family

ID=48485783

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103435 AR083066A1 (en) 2011-05-20 2011-09-20 PHARMACEUTICAL COMPOSITION

Country Status (1)

Country Link
AR (1) AR083066A1 (en)

Similar Documents

Publication Publication Date Title
CL2013003019A1 (en) Compounds derived from benzothiazole; pharmaceutical composition that includes them; and its use in the treatment of hiv.
CL2016002772A1 (en) Fast-acting insulin compositions
CL2016002971A1 (en) Combination.
CL2014003444A1 (en) Thienopyrimidine derivative compounds; Preparation process; pharmaceutical composition that includes them; pharmaceutical combination; use in the treatment of cancers and autoimmune diseases.
BR112015007642A2 (en) progesterone oral kits and dosage forms.
CL2016000042A1 (en) Use of a combination of a mek inhibitor and an erk inhibitor for the treatment of hyperproliferative diseases.
GT201200284A (en) PHARMACEUTICAL COMPOSITION
CL2013003577A1 (en) Use of a pharmaceutical composition comprising panobinostat and ruxolitinib in the prevention and / or treatment of myeloproliferative neoplasms.
IT1403847B1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING RIFAXIMINA AND THEIR USE.
CO7160079A2 (en) Liquid racecadotillo compositions
CL2015002180A1 (en) Combination therapy for the treatment of nosocomial pneumonia
GT201200304A (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE HYDROMORPHONE AND NALOXONE
BR112013027403A2 (en) compositions comprising a selenium glucose and antimetabolite
SMT201600154B (en) ORVLNOL AND TEVINOL DERIVATIVES USEFUL IN THE TREATMENT OF AN ABUSE OF DRUGS AND ALCOHOL
UY34166A (en) TYPICAL OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB
CL2012003265A1 (en) Tamarind seed polysaccharide for use in the treatment of infectious diseases; pharmaceutical and / or anti-inflammatory dermocosmetic composition containing said polysaccharide; use of a tamarind seed polysaccharide.
CO6700840A2 (en) Theobromine in combination with an expectorant or mucolytic for use in therapy
CL2012001757A1 (en) 8-hydroxyquinoline-7-carboxamide derived compounds; pharmaceutical composition; and its use in the treatment of fungal infections.
BR112013023575A2 (en) “octahydrothienoquinoline derivative, pharmaceutical composition comprising the derivative, and use thereof”
CL2013000335A1 (en) Highly crystalline form of valsartan; process to prepare it; pharmaceutical composition that understands it and use in the treatment of hypertension.
ECSP15050273A (en) ORAL FORMULATION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
CL2015001502A1 (en) Pharmaceutical composition comprising desloratadine and prendnisolone and use thereof.
CL2015000610A1 (en) Isoxazolidine derivatives
CL2010001594A1 (en) Use of nifurtimox to prepare a medicine useful in the treatment of diseases caused by trichomonadide.
CL2014000595A1 (en) Cynara extract; pharmaceutical composition that contains it; and its use for the treatment of hyperglycemia, hypercholesterolemia, hypertension and hepatic steatosis.

Legal Events

Date Code Title Description
FB Suspension of granting procedure